ClinVar Miner

Submissions for variant NM_000310.4(PPT1):c.529C>G (p.Gln177Glu)

gnomAD frequency: 0.00003  dbSNP: rs386833650
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000188719 SCV000242343 pathogenic not provided 2022-03-30 criteria provided, single submitter clinical testing Reported previously in individuals with late-infantile neuronal ceroid lipofuscinosis who harbored a second PPT1 variant in unknown phase (Das et al., 1998; Waliany et al., 2000); Published functional studies demonstrate significantly reduced enzyme activity in the presence of the Q177E mutation (Das et al., 2001); Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 19793631, 10649502, 12125808, 21990111, 11073228, 9664077, 11440996)
Invitae RCV000049609 SCV000762916 pathogenic Neuronal ceroid lipofuscinosis 1 2024-01-08 criteria provided, single submitter clinical testing This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 177 of the PPT1 protein (p.Gln177Glu). This variant is present in population databases (rs386833650, gnomAD 0.008%). This missense change has been observed in individual(s) with late onset neuronal ceroid lipofuscinoses (PMID: 9664077). ClinVar contains an entry for this variant (Variation ID: 56198). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PPT1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects PPT1 function (PMID: 11440996). For these reasons, this variant has been classified as Pathogenic.
Eurofins Ntd Llc (ga) RCV000188719 SCV000861264 pathogenic not provided 2018-05-30 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000049609 SCV000915409 pathogenic Neuronal ceroid lipofuscinosis 1 2017-04-28 criteria provided, single submitter clinical testing The PPT1 c.529C>G (p.Gln177Glu) missense variant has been reported in a compound heterozygous state in five unrelated individuals with neuronal ceroid lipofuscinosis (NCL) (Das et al. 1998; Waliany et al. 2000; Kousi et al. 2012). Three individuals were affected with late-infantile NCL with the age of onset not reported in the other two subjects. The p.Gln177Glu variant was absent from 60 controls subjects but is reported at a frequency of 0.00007 in the European (non-Finnish) population of the Exome Aggregation Consortium. An enzyme activity of 7.3% of normal was detected in COS cells transfected with the p.Gln177Glu variant, while enzyme levels of 1.08% that of control was detected in lymphoblasts from an individual carrying the p.Gln177Glu variant (Das et al. 2001). Furthermore, kinetic analysis on highly purified variant protein using Sf9 insect cells revealed that the p.Gln177Glu variant led to substrate binding defects compared to wild type (Das et al. 2001). Based on the evidence, the p.Gln177Glu variant is classified as pathogenic for autosomal recessive neuronal ceroid lipofuscinosis. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Baylor Genetics RCV000049609 SCV004204165 pathogenic Neuronal ceroid lipofuscinosis 1 2022-12-22 criteria provided, single submitter clinical testing
Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) RCV000049609 SCV000082016 probable-pathogenic Neuronal ceroid lipofuscinosis 1 no assertion criteria provided not provided Converted during submission to Likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.